Mayo Foundation for Medical Education and Research

University of Utah Research Foundation

Other

Incyte Pharmaceuticals, Inc.

Donlar Corporation

Gerald J Gleich

Russell Morris Condie

Kathryn A Peterson

Hedieh Saffari

Leonard F Pease

Kristin M Leiferman

Craig G Wilde

Randy W Scott

Tsukasa Ohnishi

Loren W Hunt, Jr

Loren W Hunt

Terri L Wasmoen

Katrin Szardenings

Tarek Aboul-Fadl Mohamed

Lori A Wagner

Jennifer L Bankers-Fulbright

Aaron M Levy

Disclosed are methods of detecting eosinophil degranulation in the respiratory tract of subjects. Also, disclosed are methods of producing medical images of the respiratory tract of subjects. The method can include administering radiolabeled heparin to the respiratory tract of subjects, wherein the radiolabeled heparin binds to one or more eosinophil granule protein in the mucosal tissue of the respiratory tract.

Method of detecting eosinophil degranulation in the respiratory tract

Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment. In another aspect, disclosed is a method of diagnosing eosinophilic esophagitis or eosinophilic diseases in a subject, comprising detecting an eosinophil granule protein in the mucosal tissue of the esophagus or other organs in a subject.

Methods for diagnosing and monitoring eosinophilic esophagitis

Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment. In another aspect, disclosed is a method of diagnosing eosinophilic esophagitis or eosinophilic diseases in a subject, comprising detecting an eosinophil granule protein in the mucosal tissue of the esophagitis or other organs in a subject.

Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment.

Disclosed are compositions and methods for regulating eosinophils.

Methods and compositions related to eosinophil regulation

A therapeutic method is provided to treat neutrophil-associated pulmonary diseases, such as chronic obstructive pulmonary disease, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.

Method of treating neutrophil-related diseases with topical anesthetics

The invention provides methods which are useful for treating diseases (e.g., cancer) where PKC&dgr; is implicated, and modulation (e.g, inhibition) of its activity is desired.

Topical anesthetics useful for treating cancer

A therapeutic method comprising counteracting or preventing pathologies mediated by IL-5, including those characterized by eosinophil infiltration, degranulation and inflammation, by administering to a mammal in need of such therapy, one or more compounds that bind to the eosinophil sulfonylurea receptor, optionally in combination with one or more topical anesthetics and/or glucocorticoids.

Use of agents to treat eosinophil-associated pathologies

A diagnostic method is provided for inflammatory bowel disorders (IBD), based on the relative levels of eosinophil granule proteins in physiological samples obtained from the GI tract of mammals suspected of having an IBD.

Eosinophil granole proteins as indicators of inflammatory bowel disorders

A therapeutic method is provided to treat an eosinophil-associated pathology, such as bronchial asthma, by administering to a mammal in need of such treatment, an effective amount of at least one topical anesthetic, such as lidocaine, with an effective amount of one or more glucocorticoids, or the pharmaceutically acceptable salts thereof.

Treatment of eosinophil-associated pathologies by administration of

A method is provided for treating a hypersensitivity disease comprising parenterally administering to a human afflicted with such a disease an amount of an anionic polymer effective to counteract the symptoms of a disease selected from the group consisting of bronchial asthma, eosinophil-associated nasal inflammation and vernal conjunctivitis, by counteracting the effect of at least one cationic toxin released by the eosinophils of said human.

Method for the treatment of bronchial asthma and like hypersensitivity

Several natural polypeptides (basophil granule proteins, 'BGP') derived from the cytoplasmic granules of human basophils, and modified forms thereof, are described. These polypeptides, the DNA which encodes them and antibodies which recognize them, are useful as diagnostics for, and treatments for, pathologies involving inflammatory and IgE-mediated responses, parasitic and helminthic infections, hypersensitivity reactions and certain types of leukocytic leukemias.

Basophil granule proteins

Method for the treatment of bronchial asthma by parenteral

A therapeutic method is provided to treat eosinophil-associated hypersensitivity diseases, such as bronchial asthma, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.

Growing community of inventors

Rochester, MN, United States of America

Gerald J Gleich